盤後交易 19:00 (美東)237.600USD+0.320+0.14%關鍵數據
242.420今開
248.750最高
376.91K成交量
虧損本益比TTM
410.19本益比動
--股利TTM
0.64%換手率
242.480昨收
207.410最低
90.46M成交額
虧損本益比靜
19.53市淨率
0.00%股息率 TTM
-20.36%ROA
248.75052週最高
113.28量比
-146.37M淨利潤
58.98M總股本
-3.3024每股盈餘TTM
0.86Beta
-26.39%ROE
80.90552週最低
17.05%振幅
85.23%毛利率
14.01B總市值
6.29回報/風險
3.26%風險率

即將為您帶來更多新聞,敬請期待。 。 。
Glaukos Corp評分
0.34與上次評分對比預測8.71
財務診斷7.89
技術分析6.28
公司估值9.71
機構認同度10.00
風險評估7.61
分析師評級
買入評級
220.417目標均價
+21.49%漲幅空間
Glaukos Corp 最新財報電話會記錄
Glaukos (GKOS) 2026 年第三季法說會:上調財測指引,2027 年營收目標達 10 億美元
受 Epioxa 與 iDose TR 帶動,Glaukos 2026 年第三季銷售額成長 58% 至 2.11 億美元。管理層調升 2026 年財測指引,並提出 2027 年達 10 億美元的展望。
財務指標
貨幣: USD

由於公司未披露,未能獲取相關數據
貨幣: USD

由於公司未披露,未能獲取相關數據
Glaukos Corp 簡介
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
行業醫療設備與耗材
公司代碼GKOS
員工數量995
國家United States of America
持股情況
| 持股股東 | 佔比 |
|---|
| BlackRock Institutional Trust Company, N.A. | 13.75% |
|---|
| PRIMECAP Management Company | 5.74% |
|---|
| Vanguard Portfolio Management, LLC | 5.46% |
|---|
| Janus Henderson Investors | 5.14% |
|---|
| 股東類型 | 佔比 |
|---|
| Investment Advisor | 50.27% |
|---|
| Investment Advisor/Hedge Fund | 31.24% |
|---|
| Hedge Fund | 11.62% |
|---|
| Individual Investor | 3.59% |
|---|
常見問題
Glaukos Corp(GKOS)的當前股價是多少?
Glaukos Corp(GKOS)的當前股價是 237.60。
Glaukos Corp股票的52週最高點是多少?
Glaukos Corp股票的52週最高點是248.75。
Glaukos Corp股票的52週最低點是多少?
Glaukos Corp股票的52週最低點是80.91。
現在Glaukos Corp(GKOS)的股票是買入、持有還是賣出?
根據分析師評級,Glaukos Corp(GKOS)的總體評級為買入,目標價格為220.42。
Glaukos Corp(GKOS)股票的每股收益(EPS TTM)是多少
Glaukos Corp(GKOS)股票的每股收益(EPS TTM)是-3.30。